Researcher Profiles

Return to member profile

X. F. Steven Zheng, PhD

Publications since 2011

Tsang, C. K. Liu, Y. Thomas, J. Zhang, Y. Zheng, X. F. Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat Commun, 5:3446, . (PMID: 24647101)

Peng, H. S. Liao, M. B. Zhang, M. Y. Xie, Y. Xu, L. Zhang, Y. J. Zheng, X. F. Wang, H. Y. Chen, Y. F. Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells. PLoS One, 9:e100814, . (PMID: 24956259, PMCID: PMC4067386)

Wei, R. Huang, G. L. Zhang, M. Y. Li, B. K. Zhang, H. Z. Shi, M. Chen, X. Q. Huang, L. Zhou, Q. M. Jia, W. H. Zheng, X. F. Yuan, Y. F. Wang, H. Y. Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma. Clin Cancer Res, 19:4780-4791, . (PMID: 23812667)

Don, A. S. Tsang, C. K. Kazdoba, T. M. D'Arcangelo, G. Young, W. Zheng, X. F. Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries. Drug Discov Today, 17:861-868, . (PMID: 22569182, PMCID: PMC3411916)

Zheng, X. F. Chemoprevention of age-related macular regeneration (AMD) with rapamycin. Aging (Albany NY), 4:375-376, . (PMID: 22796653, PMCID: PMC3409673)

Zhang, Y. Zheng, X. F. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle, 11:594-603, . (PMID: 22262166, PMCID: PMC3315097)

Zhang, Y. J. Duan, Y. Zheng, X. F. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today, 16:325-331, . (PMID: 21333749, PMCID: PMC3073023)

Arachchige Don, A. S. Zheng, X. F. Recent Clinical Trials of mTOR-Targeted Cancer Therapies. Rev Recent Clin Trials, 6:24-35, . (PMID: 20868343)

Wei, Y. Zheng, X. F. Nutritional control of cell growth via TOR signaling in budding yeast. Methods Mol Biol, 759:307-319, . (PMID: 21863495)